OBJECTIVE: To compare variation in the HIV-1 V3 neutralization domain in Tanzania and The Netherlands. METHODS: For serologic analysis, the specificity of anti-V3 antibodies (immunoglobulin G) for a panel of V3 peptides was determined in sera from 55 symptomatic HIV-1-infected Tanzanians and 51 Dutch AIDS patients. For genetic analysis, viral RNA was isolated from 15 of the Tanzanian sera and six of the Dutch sera. The V3 encoding region was reverse-transcribed, polymerase chain reaction-amplified and bacterially cloned, and sequences were determined over a stretch of at least 207 nucleotides. RESULTS: Thirty-five per cent of the Tanzanian sera, versus 2% of the Dutch sera, showed the highest reactivity to a V3 sequence of Zairian origin (RKSIHVGPGQAFYATG). Twenty-nine per cent of the Tanzanian sera, versus 82% of the Dutch sera, showed the highest reactivity to V3 sequences of US/European origin (RKSIXIGPGRAFYTTG; X = H, P or N). The Tanzanian RNA sequences showed greater diversity (mean distance, 19%) than the Dutch RNA sequences (10%). The measured anti-V3 specificities of the Tanzanian sera did not match accurately with the V3 sequences recovered from these sera. However, reactivity to the Zairian V3 peptide was associated with the sequence GPGQ, found in the centre of the V3 in 50% of the Tanzanian sequences. Sera from both countries that showed similar reactivities to the peptide panel contained RNA sequences that were relatively distant. CONCLUSIONS: The diversity of the HIV-1 population in Tanzania is much greater than that in The Netherlands. An indication of the HIV-1 V3 variation in a particular geographic region can be obtained by serological methods, but sequence analysis should not be omitted.
OBJECTIVE: To compare variation in the HIV-1 V3 neutralization domain in Tanzania and The Netherlands. METHODS: For serologic analysis, the specificity of anti-V3 antibodies (immunoglobulin G) for a panel of V3 peptides was determined in sera from 55 symptomatic HIV-1-infected Tanzanians and 51 Dutch AIDSpatients. For genetic analysis, viral RNA was isolated from 15 of the Tanzanian sera and six of the Dutch sera. The V3 encoding region was reverse-transcribed, polymerase chain reaction-amplified and bacterially cloned, and sequences were determined over a stretch of at least 207 nucleotides. RESULTS: Thirty-five per cent of the Tanzanian sera, versus 2% of the Dutch sera, showed the highest reactivity to a V3 sequence of Zairian origin (RKSIHVGPGQAFYATG). Twenty-nine per cent of the Tanzanian sera, versus 82% of the Dutch sera, showed the highest reactivity to V3 sequences of US/European origin (RKSIXIGPGRAFYTTG; X = H, P or N). The Tanzanian RNA sequences showed greater diversity (mean distance, 19%) than the Dutch RNA sequences (10%). The measured anti-V3 specificities of the Tanzanian sera did not match accurately with the V3 sequences recovered from these sera. However, reactivity to the Zairian V3 peptide was associated with the sequence GPGQ, found in the centre of the V3 in 50% of the Tanzanian sequences. Sera from both countries that showed similar reactivities to the peptide panel contained RNA sequences that were relatively distant. CONCLUSIONS: The diversity of the HIV-1 population in Tanzania is much greater than that in The Netherlands. An indication of the HIV-1 V3 variation in a particular geographic region can be obtained by serological methods, but sequence analysis should not be omitted.
Entities:
Keywords:
Africa; Africa South Of The Sahara; Antibodies--analysis; Biology; Developed Countries; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Europe; Examinations And Diagnoses; Genetic Technics; Hiv Infections; Immunity; Immunologic Factors; Laboratory Examinations And Diagnoses; Laboratory Procedures; Netherlands; Physiology; Tanzania; Viral Diseases; Western Europe
Authors: Simon A A Travers; Jonathan P Clewley; Judith R Glynn; Paul E M Fine; Amelia C Crampin; Felix Sibande; Dominic Mulawa; James O McInerney; Grace P McCormack Journal: J Virol Date: 2004-10 Impact factor: 5.103
Authors: I Loussert-Ajaka; M L Chaix; B Korber; F Letourneur; E Gomas; E Allen; T D Ly; F Brun-Vézinet; F Simon; S Saragosti Journal: J Virol Date: 1995-09 Impact factor: 5.103
Authors: L Buonaguro; E Del Guadio; M Monaco; D Greco; P Corti; E Beth-Giraldo; F M Buonaguro; G Giraldo Journal: J Virol Date: 1995-12 Impact factor: 5.103
Authors: Ireen E Kiwelu; Vladimir Novitsky; Lauren Margolin; Jeannie Baca; Rachel Manongi; Noel Sam; John Shao; Mary F McLane; Saidi H Kapiga; M Essex Journal: PLoS One Date: 2012-10-31 Impact factor: 3.240
Authors: Dennis Maletich Junqueira; Eduan Wilkinson; Ana Vallari; Xianding Deng; Asmeeta Achari; Guixia Yu; Carole McArthur; Lazare Kaptue; Dora Mbanya; Charles Chiu; Gavin A Cloherty; Tulio de Oliveira; Mary A Rodgers Journal: AIDS Res Hum Retroviruses Date: 2020-05-18 Impact factor: 2.205